Expert Insights from PALOMA-3: Highlights from ASCO 2024

Opinion
Video

Wade T. Iams, MD, outlines insights gleaned from recently presented data from the PALOMA-3 trial in advanced EGFR-mutant non–small cell lung cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
2 experts in this video
Related Content